Clinical Trial Update: Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). [Phase 3]

View source ↗

Summary

A multicenter open-label Phase 3 study evaluating adding isatuximab to lenalidomide and dexamethasone, with or without bortezomib, in newly diagnosed non-frail …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Revlimid (lenalidomide)
• Sarclisa (isatuximab) (isatuximab)
• Velcade (bortezomib)

Snippet

Sponsor: Poitiers University Hospital | Conditions: Multiple Myeloma, Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING